InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of InflaRx (NASDAQ:IFRXFree Report) in a report published on Friday, Benzinga reports. HC Wainwright currently has a $8.00 target price on the stock.

InflaRx Price Performance

Shares of NASDAQ:IFRX opened at $1.49 on Friday. The company’s fifty day moving average price is $1.61 and its 200 day moving average price is $1.92. InflaRx has a 12 month low of $1.14 and a 12 month high of $7.25. The firm has a market capitalization of $66.60 million, a P/E ratio of -2.01 and a beta of 1.29.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in IFRX. JPMorgan Chase & Co. lifted its holdings in shares of InflaRx by 7,966.1% in the fourth quarter. JPMorgan Chase & Co. now owns 9,760 shares of the company’s stock valued at $30,000 after purchasing an additional 9,639 shares in the last quarter. Virtu Financial LLC acquired a new position in InflaRx during the first quarter worth approximately $53,000. Northern Trust Corp acquired a new position in InflaRx during the fourth quarter worth approximately $64,000. BNP Paribas Arbitrage SNC acquired a new position in InflaRx during the second quarter worth approximately $95,000. Finally, Franklin Street Advisors Inc. NC increased its position in InflaRx by 49.9% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 75,100 shares of the company’s stock worth $122,000 after purchasing an additional 25,000 shares during the last quarter. 48.23% of the stock is currently owned by institutional investors and hedge funds.

About InflaRx

(Get Free Report)

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

Featured Articles

Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with's FREE daily email newsletter.